Local and intralesional therapy of in‐transit melanoma metastases

Regional relapse of melanoma may occur as satellite or in‐transit metastases proximal to the primary tumor in the direction of the lymph flow. The management of in‐transit metastases is challenging because the efficacy of treatment is largely dictated by the biological behavior of the patient's melanoma. This review examines local treatment modalities. J. Surg. Oncol. 2011; 104:391–396. © 2011 Wiley‐Liss, Inc.

[1]  A. Testori,et al.  Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach , 2010, Dermatologic therapy.

[2]  M. Atkins,et al.  A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma , 2010, Melanoma research.

[3]  S. Kim-Schulze,et al.  Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.

[4]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Mecker G Möller,et al.  Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma , 2009, Expert review of anticancer therapy.

[6]  K. Shannon,et al.  Topical diphencyprone immunotherapy for cutaneous metastatic melanoma , 2009, The Australasian journal of dermatology.

[7]  T. Ohtani,et al.  Perilesional treatment of metastatic melanoma with interferon‐β , 2009, Clinical and experimental dermatology.

[8]  P. Hersey,et al.  Chemoablation of metastatic melanoma using intralesional Rose Bengal , 2008, Melanoma research.

[9]  S. Meijer,et al.  Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients , 2008, Clinical Cancer Research.

[10]  K. Delman,et al.  Therapy for unresectable recurrent and in-transit extremity melanoma. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[11]  P. Quaglino,et al.  Electrochemotherapy with Intravenous Bleomycin in the Local Treatment of Skin Melanoma Metastases , 2008, Annals of Surgical Oncology.

[12]  Jan J. Battermann,et al.  Local therapy of cancer with free IL-2 , 2008, Cancer Immunology, Immunotherapy.

[13]  G. O'sullivan,et al.  Electrochemotherapy: An emerging cancer treatment , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[14]  Antonella Vecchiato,et al.  Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients , 2008, Annals of Surgical Oncology.

[15]  G. Curigliano,et al.  A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors , 2007 .

[16]  D. Damian,et al.  Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. , 2007, Journal of the American Academy of Dermatology.

[17]  M. Tangney,et al.  Electrochemotherapy: Aspects of Preclinical Development and Early Clinical Experience , 2007, Annals of surgery.

[18]  A. Dalgleish,et al.  Phase I/II study of topical imiquimod and intralesional interleukin‐2 in the treatment of accessible metastases in malignant melanoma , 2007, The British journal of dermatology.

[19]  L. Mir.  Bases and rationale of the electrochemotherapy , 2006 .

[20]  C. Collins,et al.  Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes , 2006 .

[21]  J. Thompson,et al.  Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors , 2006, Expert review of anticancer therapy.

[22]  A. Cochran,et al.  Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional β-interferon injection , 2003, Melanoma research.

[23]  C. Garbe,et al.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases , 2003, British Journal of Cancer.

[24]  A. Hauschild,et al.  Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma , 2003, Melanoma research.

[25]  B. Berman,et al.  Novel dermatologic uses of the immune response modifier imiquimod 5% cream. , 2002, Skin therapy letter.

[26]  L. Ridolfi,et al.  Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. , 2002, Hepato-gastroenterology.

[27]  M. Fabbri,et al.  Intralesional granulocyte‐monocyte colony‐stimulating factor followed by subcutaneous interleukin‐2 in metastatic melanoma: a pilot study in elderly patients , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[28]  P. Triozzi,et al.  Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer , 2000, Cancer.

[29]  M. Jaroszeski,et al.  Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin , 1998, Cancer.

[30]  D. Miklavcic,et al.  Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. , 1998, British Journal of Cancer.

[31]  M. Jaroszeski,et al.  Bleomycin-mediated electrochemotherapy of metastatic melanoma. , 1996, Archives of dermatology.

[32]  P. Hersey,et al.  Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF , 1996, Melanoma research.

[33]  D. Miklavčič,et al.  Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients , 1995 .

[34]  G. Rassner,et al.  [Intralesional therapy of melanoma metastases with recombinant interferon-beta]. , 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[35]  H. Deicher,et al.  Intralesional interferon‐alpha therapy in advanced malignant melanoma , 1988, Cancer.

[36]  J. Jessup,et al.  Intralesional treatment of recurrent metastatic cutaneous malignant melanoma. A randomized prospective study of intralesional bacillus calmette‐guerin versus intralesional dinitrochlorobenzene , 1978, Cancer.

[37]  S. Rosenberg,et al.  Intralesional immunotherapy of melanoma with BCG. , 1976, The Medical clinics of North America.

[38]  W. Clark,et al.  Regression of pulmonary metastatic disease associated with intralesional bcg therapy of intracutaneous melanoma metastases , 1975 .

[39]  W. Clark,et al.  Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. , 1975, Cancer.

[40]  M. Silverstein,et al.  Complications of BCG immunotherapy in patients with cancer. , 1973, The New England journal of medicine.

[41]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.

[42]  W. Coley.  THE THERAPEUTIC VALUE OF THE MIXED TOXINS OF THE STREPTOCOCCUS OF ERYSIPELAS AND BACILLUS PRODIGIOSUS IN THE TREATEMENT OF INOPER- ABLE MALIGNANT TUMORS: WITH A REPORT OF 0NE HUNDRED AND SIXTY CASES , 1896 .